ANIP
ANI Pharmaceuticals, Inc. [ANIP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ANIP Stock Summary
Top ANIP Correlated Resources
ANIP
Top 10 Correlated ETFs
ANIP
Top 10 Correlated Stocks
ANIP
In the News
ANIP Financial details
Company Rating
Buy
Market Cap
1.41B
Income
18.78M
Revenue
486.82M
Book val./share
22.77
Cash/share
11.64
Dividend
-
Dividend %
-
Employees
642
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
78.7
Forward P/E
-
PEG
-5.98
P/S
2.53
P/B
2.32
P/C
5.55
P/FCF
21.52
Quick Ratio
2.77
Current Ratio
3.7
Debt / Equity
0.72
LT Debt / Equity
0.72
-
-
EPS (TTM)
0.93
EPS next Y
-
EPS next Q
-
EPS this Y
-132.2%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
13.25%
Revenue last 5Y
18.71%
Revenue Q/Q
-0.13%
EPS Q/Q
-92.12%
-
-
-
-
SMA20
-0.89%
SMA50
19.56%
SMA100
28.3%
Inst Own
63.2%
Inst Trans
0.85%
ROA
2%
ROE
3%
ROC
0.06%
Gross Margin
63%
Oper. Margin
10%
Profit Margin
3%
Payout
12%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
36.99-70.81
52W High
-7.74%
52W Low
+79.39%
RSI
39.84
Rel Volume
1.3
Avg Volume
141.36K
Volume
184.18K
Perf Week
-3.68%
Perf Month
-1.87%
Perf Quarter
9.48%
Perf Half Y
10.66%
-
-
-
-
Beta
0.802
-
-
Volatility
1.08%, 1.33%
Prev Close
-1.37%
Price
64.58
Change
-1.49%
ANIP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 17.44 | 17.43 | 17.16 | 19.46 | 27.04 | |
| Net income per share | 0.51 | -1.88 | -3.38 | -2.95 | 1.04 | |
| Operating cash flow per share | 3.85 | 1.28 | 0.26 | -1.92 | 6.61 | |
| Free cash flow per share | 1.53 | -4.43 | -1.61 | -2.93 | 5.58 | |
| Cash per share | 5.26 | 0.66 | 7.96 | 2.97 | 12.28 | |
| Book value per share | 17.97 | 16.36 | 28.48 | 20.82 | 24.04 | |
| Tangible book value per share | 2.43 | 0.3 | 2.92 | 3.61 | 10.86 | |
| Share holders equity per share | 17.97 | 16.36 | 28.48 | 20.82 | 24.04 | |
| Interest debt per share | 16.78 | 16.31 | 23.76 | 19.35 | 18.78 | |
| Market cap | 730.23M | 347.43M | 580.42M | 654.14M | 992.58M | |
| Enterprise value | 853.65M | 525.26M | 767.49M | 892.43M | 1.09B | |
| P/E ratio | 119.83 | -15.41 | -13.62 | -13.66 | 52.86 | |
| Price to sales ratio | 3.54 | 1.67 | 2.69 | 2.07 | 2.04 | |
| POCF ratio | 16 | 22.76 | 174.72 | -20.96 | 8.34 | |
| PFCF ratio | 40.38 | -6.55 | -28.57 | -13.73 | 9.88 | |
| P/B Ratio | 3.43 | 1.78 | 1.62 | 1.93 | 2.29 | |
| PTB ratio | 3.43 | 1.78 | 1.62 | 1.93 | 2.29 | |
| EV to sales | 4.13 | 2.52 | 3.55 | 2.82 | 2.23 | |
| Enterprise value over EBITDA | 14.04 | 18.38 | 52.07 | 27.97 | 9.94 | |
| EV to operating cash flow | 18.71 | 34.4 | 231.03 | -28.6 | 9.14 | |
| EV to free cash flow | 47.21 | -9.9 | -37.78 | -18.73 | 10.82 | |
| Earnings yield | 0.01 | -0.06 | -0.07 | -0.07 | 0.02 | |
| Free cash flow yield | 0.02 | -0.15 | -0.04 | -0.07 | 0.1 | |
| Debt to equity | 0.87 | 0.95 | 0.8 | 0.85 | 0.72 | |
| Debt to assets | 0.41 | 0.4 | 0.37 | 0.38 | 0.34 | |
| Net debt to EBITDA | 2.03 | 6.22 | 12.69 | 7.47 | 0.86 | |
| Current ratio | 3.04 | 2.17 | 3.68 | 3.46 | 3.57 | |
| Interest coverage | 1.26 | -1.7 | -2.73 | -0.89 | 1.8 | |
| Income quality | 7.49 | -0.68 | -0.08 | 0.65 | 6.33 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.94 | -0.03 | 0 | -0.03 | 0.09 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.1 | 0.08 | 0.05 | 0.07 | 0.07 | |
| Intangibles to total assets | 0.4 | 0.42 | 0.42 | 0.37 | 0.26 | |
| Capex to operating cash flow | -0.6 | -4.48 | -7.12 | 0.53 | -0.16 | |
| Capex to revenue | -0.13 | -0.33 | -0.11 | -0.05 | -0.04 | |
| Capex to depreciation | -0.62 | -1.53 | -0.5 | -0.28 | -0.31 | |
| Stock based compensation to revenue | 0.04 | 0.06 | 0.05 | 0.05 | 0.04 | |
| Graham number | 14.43 | 26.34 | 46.56 | 37.15 | 23.75 | |
| ROIC | 0.08 | -0.04 | -0.04 | -0.03 | 0.06 | |
| Return on tangible assets | 0.02 | -0.08 | -0.09 | -0.1 | 0.03 | |
| Graham Net | -8.74 | -12.99 | -13.92 | -12.09 | -4.08 | |
| Working capital | 126.02M | 91.76M | 234.24M | 244.82M | 374.14M | |
| Tangible asset value | 28.82M | 3.61M | 36.73M | 58.68M | 195.52M | |
| Net current asset value | -56.3M | -95.17M | -91.08M | -77.29M | 47.94M | |
| Invested capital | 0.87 | 0.95 | 0.8 | 0.85 | 0.72 | |
| Average receivables | 68.49M | 83.96M | 112.16M | 146.98M | 163.76M | |
| Average payables | 11.75M | 12.93M | 17.11M | 26.14M | 32.99M | |
| Average inventory | 44.33M | 54.48M | 71.25M | 93.52M | 108.28M | |
| Days sales outstanding | 127.46 | 167.72 | 217.05 | 190.86 | 121.52 | |
| Days payables outstanding | 84.42 | 47.16 | 83.32 | 77.07 | 55.49 | |
| Days of inventory on hand | 278.36 | 254.63 | 296.37 | 277.08 | 168.2 | |
| Receivables turnover | 2.86 | 2.18 | 1.68 | 1.91 | 3 | |
| Payables turnover | 4.32 | 7.74 | 4.38 | 4.74 | 6.58 | |
| Inventory turnover | 1.31 | 1.43 | 1.23 | 1.32 | 2.17 | |
| ROE | 0.03 | -0.12 | -0.12 | -0.14 | 0.04 | |
| Capex per share | -2.33 | -5.71 | -1.88 | -1.01 | -1.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.77 | 6.51 | 6.59 | 6.98 | 6.93 | |
| Net income per share | -0.26 | 0.09 | 0.35 | 0.53 | 0.06 | |
| Operating cash flow per share | -0.27 | 1.31 | 1.17 | 1.7 | 2.35 | |
| Free cash flow per share | -0.46 | 1.16 | 0.78 | 1.46 | 2.1 | |
| Cash per share | 2.95 | 4.13 | 9.14 | 10.22 | 11.64 | |
| Book value per share | 20.74 | 20.71 | 24.56 | 24.08 | 22.77 | |
| Tangible book value per share | 3.59 | 4.42 | 9.95 | 10.94 | 10.29 | |
| Share holders equity per share | 20.74 | 20.71 | 24.56 | 24.08 | 22.77 | |
| Interest debt per share | 18.01 | 17.94 | 16.58 | 15.48 | 16.63 | |
| Market cap | 656.75M | 651.09M | 952.15M | 1.1B | 1.05B | |
| Enterprise value | 895.05M | 869.64M | 1.08B | 1.19B | 1.14B | |
| P/E ratio | -38.7 | 113.12 | 38.12 | 27.57 | 226.8 | |
| Price to sales ratio | 6.97 | 6.1 | 8.17 | 8.32 | 7.96 | |
| POCF ratio | -149.26 | 30.39 | 46.16 | 34.08 | 23.42 | |
| PFCF ratio | -87.08 | 34.14 | 69 | 39.7 | 26.22 | |
| P/B Ratio | 1.94 | 1.92 | 2.19 | 2.41 | 2.42 | |
| PTB ratio | 1.94 | 1.92 | 2.19 | 2.41 | 2.42 | |
| EV to sales | 9.5 | 8.14 | 9.24 | 9.02 | 8.67 | |
| Enterprise value over EBITDA | 46.01 | 32.63 | 38.34 | 38.91 | 47.77 | |
| EV to operating cash flow | -203.42 | 40.59 | 52.19 | 36.97 | 25.53 | |
| EV to free cash flow | -118.67 | 45.6 | 78.01 | 43.06 | 28.58 | |
| Earnings yield | -0.01 | 0 | 0.01 | 0.01 | 0 | |
| Free cash flow yield | -0.01 | 0.03 | 0.01 | 0.03 | 0.04 | |
| Debt to equity | 0.85 | 0.84 | 0.66 | 0.63 | 0.72 | |
| Debt to assets | 0.38 | 0.37 | 0.33 | 0.32 | 0.34 | |
| Net debt to EBITDA | 12.25 | 8.2 | 4.43 | 3.04 | 3.94 | |
| Current ratio | 3.46 | 2.9 | 3.74 | 3.7 | 3.57 | |
| Interest coverage | 0.66 | 1.29 | 1.75 | 2.81 | 1.56 | |
| Income quality | 1.04 | 14.89 | 3.3 | 3.24 | 38.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.1 | 0.28 | 0.07 | 0.04 | 0.35 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.06 | 0.06 | 0.06 | 0.08 | 0.07 | |
| Intangibles to total assets | 0.37 | 0.35 | 0.3 | 0.28 | 0.26 | |
| Capex to operating cash flow | 0.71 | -0.11 | -0.33 | -0.14 | -0.11 | |
| Capex to revenue | -0.03 | -0.02 | -0.06 | -0.03 | -0.04 | |
| Capex to depreciation | -0.2 | -0.16 | -0.46 | -0.3 | -0.31 | |
| Stock based compensation to revenue | 0.04 | 0.04 | 0.05 | 0.04 | 0.04 | |
| Graham number | 11.01 | 6.4 | 13.97 | 16.89 | 5.58 | |
| ROIC | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Return on tangible assets | -0.01 | 0 | 0.01 | 0.02 | 0 | |
| Graham Net | -12.04 | -10.68 | -4.6 | -2.9 | -3.86 | |
| Working capital | 244.82M | 238.93M | 336.45M | 362.87M | 374.14M | |
| Tangible asset value | 58.68M | 72.47M | 175.95M | 206.66M | 195.52M | |
| Net current asset value | -77.29M | -60.99M | 34.44M | 62.02M | 47.94M | |
| Invested capital | 0.85 | 0.84 | 0.66 | 0.63 | 0.72 | |
| Average receivables | 152.94M | 170.08M | 173.82M | 175.88M | 170.46M | |
| Average payables | 24.15M | 31M | 30.6M | 31.29M | 35.38M | |
| Average inventory | 100.62M | 104.5M | 103.99M | 105.46M | 108.89M | |
| Days sales outstanding | 158.01 | 147.25 | 133.54 | 122.1 | 110.8 | |
| Days payables outstanding | 72.61 | 78.02 | 60.67 | 63.76 | 48.12 | |
| Days of inventory on hand | 261.02 | 247.4 | 222.05 | 199.44 | 145.85 | |
| Receivables turnover | 0.57 | 0.61 | 0.67 | 0.74 | 0.81 | |
| Payables turnover | 1.24 | 1.15 | 1.48 | 1.41 | 1.87 | |
| Inventory turnover | 0.34 | 0.36 | 0.41 | 0.45 | 0.62 | |
| ROE | -0.01 | 0 | 0.01 | 0.02 | 0 | |
| Capex per share | -0.19 | -0.14 | -0.39 | -0.24 | -0.25 |
ANIP Frequently Asked Questions
What is ANI Pharmaceuticals, Inc. stock symbol ?
ANI Pharmaceuticals, Inc. is a US stock , located in Baudette of Mn and trading under the symbol ANIP
What is ANI Pharmaceuticals, Inc. stock quote today ?
ANI Pharmaceuticals, Inc. stock price is $64.58 today.
Is ANI Pharmaceuticals, Inc. stock public?
Yes, ANI Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 141.36K
- Market Capitalization 1.41B
- Employee 642
- CEO Mr. Nikhil Lalwani
- Headquarters Baudette,MN,US
- IPO Date 2000-05-05
-
Website
https://www.anipharmaceuticals.com 
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
